

Spontaneous abortion and NSAIDs

Nakhai-Pour and colleagues¹ reported a possible increased risk of spontaneous abortion associated with any type or dose of nonsteroidal anti-inflammatory drug (NSAID). This finding supports earlier work by Nielsen and colleagues² — which is not surprising, given that a combination of population-based prescription drug registries and pregnancy outcome databases was used in both studies. A criticism of the design of the earlier study³ can also be made of the later study. Filling a prescription does not adequately represent actual use of the drug prescribed, thereby rendering the findings unreliable. Nakhai-Pour and colleagues¹ do provide a reference that supports the validation of risk-assessment studies using the Régie de l'assurance maladie du Québec prescription drug database for pregnant women, but the citation is from their own institution and includes one of their coauthors,⁴ thus raising the possibility that the validation is lacking the necessary degree of independence or objectivity.

The authors stated that “to their knowledge,” neither smoking nor body mass index (BMI) are risk factors for spontaneous abortion and therefore neither needed to be considered as a confounding factor in their analyses. They cite their own work as the source for this statement.⁵ Not only maternal, but also paternal and environmental exposure to smoking have been reported to be associated with an increased incidence of spontaneous miscarriage.⁶

A recent meta-analysis of the effect of BMI on spontaneous abortion reported that patients with a BMI greater than 25 kg/m² have significantly higher odds of miscarriage regardless of the method of conception,⁷ and evidence-based guidelines for the investigation and treatment of recurrent miscarriage include BMI as a risk factor.⁸ Nakhai-Pour and colleagues¹ were not able to ascertain the smoking and BMI status of their cohorts because of their study

design, but we suggest that not considering these factors puts their findings further in question.

We believe that it would be interesting if the authors were to compare the obstetric histories and pre-existing comorbidities of the subgroup of women who filled prescriptions for nonaspirin NSAID and had a live birth ($n = 1213$) with the subgroup that filled the same prescriptions but had a spontaneous abortion ($n = 352$). This might reveal a distinct demographic at increased risk of miscarriage.

Because this was a population-based study, the authors were unable to assess usage of over-the-counter NSAIDs. In 2005, Werler and colleagues⁹ reported that the use of over-the-counter medications is extremely common during pregnancy. That an association between a common occurrence and a rare marker cannot be shown may be an epidemiologic truism. However, if an association between two common events, such as NSAID use and spontaneous abortion, exists it should be possible to find. A study is required that includes the use of both over-the-counter and prescription NSAIDs during pregnancy and, the analysis must control for all known confounding factors for each event. Until then, we are left with studies such as this one — that provide subsets of data that suggest an association but do not adequately support their claims.

Christine A. Clark PhD

Karen A. Spitzer MSc

Carl A. Laskin MD

University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, Ont.

Gideon Koren MD

Hospital for Sick Children, University of Toronto, Toronto, Ont and University of Western Ontario, London, Ont.

References

1. Nakhai-Pour HR, Broy P, Sheehy O, et al. Use of nonaspirin anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. *CMAJ* 2011;183:1713-20.
2. Nielsen GI, Sørensen HT, Larsen H, et al. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population-based observational study and case-control study. *BMJ* 2001;322:266-70.

3. Chan LY, Yuen PM. Risk of miscarriage in pregnant users of NSAIDs: more information is needed to be able to interpret study's results [letter]. *BMJ* 201;322:1365-6.
4. Bérard A, Lacasse A. Validity of perinatal pharmacoepidemiologic studies using data from the RAMQ administrative database. *Can J Clin Pharmacol* 2009;16:e360-9.
5. Nakhai-Pour HR, Broy P, Berard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. *CMAJ* 2010;182:1031-7.
6. Blanco-Muñoz J, Torres-Sanchez L, Lopez-Carrillo L. Exposure to maternal and paternal tobacco consumption and risk of spontaneous abortion. *Public Health Rep* 2009;124:317-22.
7. Metwally M, Ong KJ, Ledger WL, et al. Does high body mass index increase the risk of miscarriage after spontaneous and assisted conception? A meta-analysis of the evidence. *Fertil Steril* 2008;90:714-26.
8. Jauniaux E, Farquharson RG, Christiansen OB, et al. Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage. *Hum Reprod* 2006;21:2216-22.
9. Werler MM, Mitchell AA, Hernandez-Diaz S, et al. National Birth Defects Prevention Study. Use of over-the-counter medications during pregnancy. *Am J Obstet Gynecol* 2005;193:771-7.

CMAJ 2011. DOI:10.1503/cmaj.111-2092

The authors respond:

We disagree with Clark and colleagues.¹ Given that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is on an acute basis, even when used for chronic conditions, women who took the time to go to the pharmacy most likely took at least one pill. Glover and colleagues² have shown that most pregnant women who fill a prescription take it, and Daniels and colleagues³ have shown that self-reporting measures of medication use do not provide accurate measurements when compared with electronic monitoring, as was done in our study.⁴

Data on maternal smoking and body mass index (BMI) were available only for a subset of women included in our registry. However, these variables would need to confound the effect to bias our results. For smoking and BMI to be confounders, they would need to be associated with both outcome and exposure. Delaney and colleagues⁵ have shown that smoking and BMI are not associated with use of NSAIDs that are prescribed or over the counter.

The registry includes data on the use of prescription medication during gestation. We looked at over-the-counter ibuprofen obtained with a prescription; however, the number of women who used over-the-counter ibuprofen with-

out a prescription could not be measured. There is no reason to believe that women who miscarried used over-the-counter ibuprofen without a prescription differently than those who did not. Hence, this led to nondifferential misclassification, and our results are underestimates of the true effects.

The aim of our study was to empower women by informing them and their physicians of the potential risks of medication use during pregnancy.

Anick Bérard PhD

Faculty of Pharmacy, University of Montreal; and the Research Center, Centre hospitalier universitaire Ste-Justine, Montréal, Que.

Odile Sheehy MSc

The Research Center, Centre hospitalier universitaire Ste-Justine, Montréal, Que.

References

1. Clark CA, Spitzer KA, Laskin CA, et al. Spontaneous abortion and NSAIDs. *CMAJ* 2011;183:2145.
2. Glover DD, Amonkar M, Rybeck BF, et al. Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. *Am J Obstet Gynecol* 2003;188:1039-45.
3. Daniels T, Goodacre L, Sutton C, et al. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. *Chest* 2011;140:425-32.
4. Nakhai-Pour HR, Broy P, Sheehy O, et al. Use of nonaspirin anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. *CMAJ* 2011;183:1713-20.
5. Delaney JA, Biggs ML, Kronmal RA, et al. Demographic, medical, and behavioral characteristics associated with over the counter non-steroidal anti-inflammatory drug use in a population-based cohort: results from the Multi-Ethnic Study of Atherosclerosis. *Pharmacoepidemiol Drug Saf* 2011; 20:83-9.

CMAJ 2011. DOI:10.1503/cmaj.111-2093

Childhood aggression: response to commentary

As an author of a research article that appears in this issue,¹ I wish to respond to the related commentary by Stewart-Brown.² An encrypted identity-protecting coding procedure was thoroughly reviewed by Commission d'accès à l'information du Québec before it permitted release of Medicare records for research purposes. Analyses were done on entirely denormalized data (no names attached). Every measure was taken to respect the confidentiality of the participants, and all procedures were reviewed by the Concordia University Institutional Review Board for conformity with ethi-

cal requirements for research. Our procedures are designed to correspond to the highest international standards for protecting confidentiality of participants. Ethical guidelines for parental consent have changed dramatically in the 30 years since the Concordia Project's inception, and the "opt-out" approach to consent would no longer be considered sufficient in Canada. However, the data were entirely confidential and protected the privacy of participants.

Caroline E. Temcheff PhD

Département de psychoéducation, Université de Sherbrooke, Sherbrooke, Que.

References

1. Temcheff CE, Serbin LA, Martin-Storey A, et al. Childhood aggression, withdrawal and likeability, and the use of health care later: a longitudinal study. *CMAJ* 2011;183:2095-101.
2. Stewart-Brown S. Could parenting programs lead to lower health care costs in future generations? *CMAJ* 2011;183:2083-4.

CMAJ 2011. DOI:10.1503/cmaj.111-2100

Some letters have been abbreviated for print. See www.cmaj.ca for full versions and competing interests.

CORRECTION

Author affiliations

The employment information for Dr. Michel Joffres and Dr. Gabriela Lewin was incorrect in the guidelines¹ that appeared in the Nov. 22, 2011, issue of *CMAJ*. Dr. Joffres is affiliated with the Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia. Dr. Lewin is an associate physician with the Kemptville District Hospital in Kemptville, Ontario. Dr. Lewin is not an employee of the hospital. We apologize for any inconvenience these errors have caused.

Reference

1. The Canadian Task Force on Preventive Health Care. Recommendations on screening for breast cancer in average-risk women aged 40–74 years. *CMAJ* 2011;183:1991-2001.

CMAJ 2011. DOI:10.1503/cmaj.111-2101